- Home
- KLTR vs IMMP Comparison
KLTR vs IMMP Comparison
Compare KLTR & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KLTR
- IMMP
- Stock Information
- Founded
- KLTR 2006
- IMMP 1987
- Country
- KLTR United States
- IMMP Australia
- Employees
- KLTR N/A
- IMMP N/A
- Industry
- KLTR EDP Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- KLTR Technology
- IMMP Health Care
- Exchange
- KLTR Nasdaq
- IMMP Nasdaq
- Market Cap
- KLTR 302.6M
- IMMP 244.5M
- IPO Year
- KLTR 2021
- IMMP N/A
- Fundamental
- Price
- KLTR $1.71
- IMMP $1.72
- Analyst Decision
- KLTR Buy
- IMMP Buy
- Analyst Count
- KLTR 3
- IMMP 1
- Target Price
- KLTR $2.83
- IMMP $7.00
- AVG Volume (30 Days)
- KLTR 298.4K
- IMMP 75.4K
- Earning Date
- KLTR 08-07-2025
- IMMP 02-27-2025
- Dividend Yield
- KLTR N/A
- IMMP N/A
- EPS Growth
- KLTR N/A
- IMMP N/A
- EPS
- KLTR N/A
- IMMP N/A
- Revenue
- KLTR $180,920,000.00
- IMMP $3,019,249.00
- Revenue This Year
- KLTR $3.46
- IMMP $50.37
- Revenue Next Year
- KLTR $3.67
- IMMP N/A
- P/E Ratio
- KLTR N/A
- IMMP N/A
- Revenue Growth
- KLTR 2.40
- IMMP 24.11
- 52 Week Low
- KLTR $1.06
- IMMP $1.32
- 52 Week High
- KLTR $2.82
- IMMP $2.72
- Technical
- Relative Strength Index (RSI)
- KLTR 36.59
- IMMP 45.13
- Support Level
- KLTR $1.65
- IMMP $1.67
- Resistance Level
- KLTR $1.88
- IMMP $1.81
- Average True Range (ATR)
- KLTR 0.09
- IMMP 0.05
- MACD
- KLTR -0.01
- IMMP 0.00
- Stochastic Oscillator
- KLTR 14.91
- IMMP 30.65
About KLTR Kaltura Inc.
Kaltura Inc provides live and on-demand video SaaS solutions to thousands of organizations around the world, engaging hundreds of millions of viewers at home, at work, and at school. It also offers specialized industry solutions, including Learning Management System Video, Lecture Capture, and Virtual Classroom for educational institutions, as well as a TV Solution for media and telecom companies. It operates in two reporting segments which are Enterprise, Education, and Technology, and Media and Telecom. The majority of the revenue is derived from Enterprise, Education & Technology. The majority of the revenue is earned from the United States.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.